title: Prognostic factors of recurrent respiratory papillomatosis from a registry of 72 patients.
abstract: CONCLUSIONS
  The database revealed severity factors relating to human papillomavirus (HPV) type and age at diagnosis. While not exhaustive, the database is easy to use and could serve for a European multicentre epidemiological study.
  
  
  OBJECTIVE
  To propose a database as a starting point for a national registry and to estimate prognostic factors in recurrent respiratory papillomatosis (RRP).
  
  
  METHODS
  This was a retrospective study carried out in a tertiary care teaching hospital. From January 2005 to July 2007, epidemiological, clinical and treatment information on patients undergoing endoscopy for RRP in the department was entered in a database. Data were collected on three forms: the first comprised information about disease history before assessment in the department, the second about the disease and its treatment in the department, and the third about evolution after treatment.
  
  
  RESULTS
  Data on 72 patients were entered into an RRP database between January 2005 and July 2007. In all, 82% had already been treated for RRP in a different centre; 24 had juvenile-onset (JORRP) and 48 adult-onset (AORRP) papillomatosis. Cidovir injections had been administered to 91% of the patients. Histology found nine cases of dysplasia, one of carcinoma in situ and one of invasive carcinoma. Subglottic and tracheal locations were significantly more frequent in JORRP than in AORRP, as were the maximum Derkay scores and annual numbers of endoscopies. Patients with type 11 HPV had significantly more endoscopies per year than those with type 6.
authors.affiliation: Département d'Oto-Rhino-Laryngologie, Hôpital Edouard Herriot, Lyon, France. martinscarvalho@aliceadsl.fr
authors.forename: Christine Martins
authors.initials: CM
authors.lastname: Carvalho
authors.forename: Laure
authors.initials: L
authors.lastname: Huot
authors.forename: Anne-Laure
authors.initials: AL
authors.lastname: Charlois
authors.forename: Sonia Ayari
authors.initials: SA
authors.lastname: Khalfallah
authors.forename: Francois
authors.initials: F
authors.lastname: Chapuis
authors.forename: Patrick
authors.initials: P
authors.lastname: Froehlich
mesh_terms: D000328:Adult; D000970:Antineoplastic Agents / Q000627:therapeutic use; D002648:Child; D002675:Child, Preschool; D000077404:Cidofovir; D003596:Cytosine / Q000031:analogs & derivatives / Q000627:therapeutic use; D016208:Databases, Factual; D005260:Female; D005602:France / Q000453:epidemiology; D006784:Hospitals, Teaching; D052140:Human papillomavirus 11 / Q000302:isolation & purification; D052163:Human papillomavirus 6 / Q000302:isolation & purification; D006801:Humans; D007828:Laryngoscopy; D008297:Male; D063065:Organophosphonates / Q000627:therapeutic use; D010212:Papilloma / Q000175:diagnosis / Q000453:epidemiology* / Q000628:therapy / Q000821:virology; D030361:Papillomavirus Infections / Q000175:diagnosis / Q000453:epidemiology* / Q000628:therapy; D011379:Prognosis; D012042:Registries; D012142:Respiratory Tract Neoplasms / Q000175:diagnosis / Q000453:epidemiology* / Q000628:therapy / Q000821:virology; D012189:Retrospective Studies
chemical_list: D000970:Antineoplastic Agents; D063065:Organophosphonates; D003596:Cytosine; D000077404:Cidofovir